Editorial: Journal of Pharmaceutical Innovation 2.0

Stephen Scypinski¹

Published online: 11 February 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

The statements contained herein are my personal views, opinions, and statements and not those of my employer.

Dear Readers of the Journal of Pharmaceutical Innovation: It is indeed an honor and a privilege to assume the role of Editor-in-Chief of this prestigious scientific publication. I wish to acknowledge and thank Jim Drennen for his many years of service as the first Editor-in-Chief as well as his mentorship of me as I served as his deputy from 2007 to the present. His leadership will be a hard act to follow; however, I have taken steps to ensure not only that the transition between him and me will be smooth but also have begun to develop and execute my own vision and mission for the journal.

Membership of the Editorial Advisory Board (EAB) has been recast. Some members have stepped down and I wish to thank them for their years of service. New members have been added and I welcome and look forward to working with them. I am also happy to report that Robert Lodder, Professor in the Department of Pharmaceutical Sciences at the University of Kentucky, has accepted the position of Deputy Editor-in-Chief. The journal's two Associate Editors, Wilson Meng of Duquesne University and Douglas Both of Bristol-Myers Squibb, will continue in their current roles.

What is my vision for the Journal of Pharmaceutical Innovation? Stated simply, I wish this journal to continue

to grow, flourish, and provide a meaningful avenue for authors to publish their work. We will not attempt to compete with other journals but will supplement them and seek to increasingly add value to the scientific community. What do I need from you, the dedicated readers? I need your continued support of the Journal of Pharmaceutical Innovation through your readership and contributions in the way of original research, perspective, and review articles. Moving forward, me and my EAB will strive to deliver to you more in the way of thematic issues highlighting hot topics in the pharmaceutical industry. The journal also needs qualified and willing reviewers of the vast array of submitted manuscripts. If you are interested in being considered a reviewer for the Journal of Pharmaceutical Innovation or have any ideas to make this a better scientific publication, I invite you to write me at sscypinski@comcast.net

I look forward to the continued growth and prosperity of the Journal of Pharmaceutical Innovation. Thank you once again for your support.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Stephen Scypinski
sscypinski@comcast.net

¹ Daiichi Sankyo, Inc., 211 Mount Airy Road Room 2C-255, Basking Ridge, NJ 07920, USA